Septerna (NASDAQ:SEPN) Coverage Initiated by Analysts at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald started coverage on shares of Septerna (NASDAQ:SEPN) in a report released on Tuesday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 112.31% from the stock’s current price.

Separately, TD Cowen started coverage on shares of Septerna in a report on Tuesday. They issued a “buy” rating on the stock.

Septerna Stock Up 4.5 %

Shares of Septerna stock opened at $23.55 on Tuesday. Septerna has a one year low of $18.62 and a one year high of $26.34.

Insider Buying and Selling at Septerna

In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the stock in a transaction on Monday, October 28th. The shares were purchased at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.